Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) announces the sale of 15 ACP-01 Therapy Convertible Debentures for USD $517,230, pending TSXV Exchange approval. Year-to-date forward sales total CAD $1,149,983, providing non-dilutive working capital.
The company's production capacity is scaling from 20 to 40 treatments per month, and from 40 to 80 treatments monthly. At 20 treatments per month, annual revenue potential is USD $8,880,000 (CAD $12,876,000), with potential to quadruple with one physician performing four blood draws daily.
Each ACP-01 therapy convertible debenture (TCD) is unsecured, convertible into therapy on first-purchased basis, transferable, and earns 6% annual interest payable in shares. TCDs may be listed for trading in the future.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) annuncia la vendita di 15 Obbligazioni Convertibili per la Terapia ACP-01 per un importo di USD $517,230, in attesa dell'approvazione della Borsa TSXV. Le vendite totali dall'inizio dell'anno ammontano a CAD $1,149,983, fornendo capitale di lavoro non diluitivo.
La capacità produttiva dell'azienda sta aumentando da 20 a 40 trattamenti al mese, e da 40 a 80 trattamenti mensili. Con 20 trattamenti al mese, il potenziale di ricavi annuali è di USD $8,880,000 (CAD $12,876,000), con la possibilità di quadruplicare con un medico che effettua quattro prelievi di sangue al giorno.
Ogni obbligazione convertibile per la terapia ACP-01 (TCD) è non garantita, convertibile in terapia sulla base del primo acquisto, trasferibile e guadagna un interesse annuale del 6% pagabile in azioni. Le TCD potrebbero essere quotate per il trading in futuro.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) anuncia la venta de 15 Bonos Convertibles de Terapia ACP-01 por un total de USD $517,230, a la espera de la aprobación de la Bolsa TSXV. Las ventas acumuladas hasta la fecha ascienden a CAD $1,149,983, proporcionando capital de trabajo no dilutivo.
La capacidad de producción de la empresa está aumentando de 20 a 40 tratamientos por mes, y de 40 a 80 tratamientos mensuales. Con 20 tratamientos al mes, el potencial de ingresos anuales es de USD $8,880,000 (CAD $12,876,000), con la posibilidad de cuadruplicarse con un médico realizando cuatro extracciones de sangre al día.
Cada bono convertible de terapia ACP-01 (TCD) es no garantizado, convertible en terapia en la base de la primera compra, transferible y genera un interés anual del 6% pagadero en acciones. Los TCD podrían ser listados para negociación en el futuro.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF)는 USD $517,230에 15개의 ACP-01 치료 전환 사채를 판매한다고 발표했으며, TSXV 거래소의 승인을 기다리고 있습니다. 연초부터 현재까지의 판매 총액은 CAD $1,149,983로, 희석되지 않는 운영 자본을 제공합니다.
회사의 생산 능력은 월 20회 치료에서 40회로, 그리고 40회에서 80회로 확장되고 있습니다. 월 20회의 치료를 기준으로 연간 수익 잠재력은 USD $8,880,000 (CAD $12,876,000)이며, 하루에 네 번의 혈액을 채취하는 한 의사가 있을 경우 네 배로 증가할 수 있습니다.
각 ACP-01 치료 전환 사채(TCD)는 무담보이며, 최초 구매 기준으로 치료로 전환 가능하고, 양도 가능하며, 연 6%의 이자를 주식으로 지급받습니다. TCD는 향후 거래를 위해 상장될 수 있습니다.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) annonce la vente de 15 Obligations Convertibles de Thérapie ACP-01 pour un montant de USD $517,230, en attente de l'approbation de la Bourse TSXV. Les ventes cumulées depuis le début de l'année s'élèvent à CAD $1,149,983, fournissant un capital de travail non dilutif.
La capacité de production de l'entreprise passe de 20 à 40 traitements par mois, et de 40 à 80 traitements mensuels. Avec 20 traitements par mois, le potentiel de revenus annuels est de USD $8,880,000 (CAD $12,876,000), avec la possibilité de quadrupler si un médecin effectue quatre prélèvements sanguins par jour.
Chaque obligation convertible de thérapie ACP-01 (TCD) est non garantie, convertible en thérapie sur la base du premier achat, transférable et génère un intérêt annuel de 6% payable en actions. Les TCD pourraient être cotées pour le trading à l'avenir.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) gibt den Verkauf von 15 umwandelbaren Anleihen für die ACP-01-Therapie im Wert von USD $517,230 bekannt, vorbehaltlich der Genehmigung der TSXV-Börse. Die kumulierten Verkäufe seit Jahresbeginn belaufen sich auf CAD $1,149,983 und bieten nicht verwässerndes Betriebskapital.
Die Produktionskapazität des Unternehmens wird von 20 auf 40 Behandlungen pro Monat und von 40 auf 80 Behandlungen monatlich erhöht. Bei 20 Behandlungen pro Monat liegt das jährliche Umsatzpotenzial bei USD $8,880,000 (CAD $12,876,000), mit der Möglichkeit, sich zu vervierfachen, wenn ein Arzt täglich vier Blutentnahmen vornimmt.
Jede umwandelbare Anleihe für die ACP-01-Therapie (TCD) ist unbesichert, kann auf der Grundlage des ersten Kaufs in Therapie umgewandelt werden, ist übertragbar und verdient 6% jährliche Zinsen, die in Aktien ausgezahlt werden. TCDs könnten in Zukunft zum Handel gelistet werden.
- Non-dilutive capital raise of USD $517,230
- YTD forward sales of CAD $1,149,983
- Potential annual revenue of USD $8.88M at 20 treatments/month
- Scalable revenue model up to 80 treatments/month
- Sale subject to TSXV Exchange approval
- Creates debt obligation with 6% annual interest
Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina, congestive heart failure and vascular dementia, announces the sale of 15 ACP-01 Therapy Convertible Debentures for proceeds of USD
"Year-to-date, this sums to forward sales of CAD
An unsecured obligation of Hemostemix Inc., each ACP-01 therapy convertible debenture ("TCD") is convertible into an ACP-01 therapy on a first purchased basis. Transferable, saleable subject to a Hemostemix ROFR, will-able, and convertible into equity at the option of the Purchaser, each TCD collects interest at
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), and later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). Hemostemix has treated 498 patients, completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia. For more information, please visit www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the forward sales of ACP-01 including the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243378
FAQ
What is the value of Hemostemix's (HMTXF) latest ACP-01 Therapy Convertible Debenture sale?
How much revenue can Hemostemix (HMTXF) generate from 20 treatments per month?
What are the terms of Hemostemix's (HMTXF) ACP-01 Therapy Convertible Debentures?
What is Hemostemix's (HMTXF) total forward sales value for the year to date?
